iShares 1 3 Year Treasury Bond ETF vs Tango Therapeutics Inc. — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.34 (market cap $26.87B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 7.2× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 64 Days and Tango Therapeutics Inc. for 0 Days on average.
| SHY | TNGX | |
|---|---|---|
Market Cap | $26.87B | $3.75B |
Volume | 3,180,822 | 9,619,106 |
Sector | Fixed Income | Health |
52-Week High | $83.18 | $32.90 |
52-Week Low | $81.05 | $7.50 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $2.77B |
Signals from Pluang's Aura AI — not financial advice
SHY, a US stock, trades at $81.19 with minimal daily movement, reflecting stability amid broader bond market volatility. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend actions provide income, but key financial ratios are unavailable. The stock's price action is tightly range-bound with support and resistance near $81.
The outlook for SHY is cautious due to bearish technical signals and a lack of fundamental data. Risks include interest rate sensitivity and macroeconomic pressures from rising bond yields. Investment opportunities may lie in its dividend yield if fundamentals strengthen, but current sentiment and technicals suggest limited near-term upside.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →